

PRECEPTORSHIP PROGRAMME

Prostate Cancer

Multidisciplinary management,
standards of care, therapeutic targets
and future perspectives

LUGANO
SWITZERLAND

17-18 OCTOBER 2019

Co-Chairs

Karim Fizazi, FR
Silke Gillessen, CH

ESMO PRECEPTORSHIP PROGRAMME PROSTATE CANCER

Multidisciplinary management, standards of care,
therapeutic targets and future perspectives

Lugano, Switzerland
17-18 October 2019

CO-CHAIRS: Karim Fizazi, France
Silke Gilllessen, Switzerland

SPEAKERS: Elena Castro, Spain
Theo M. de Reijke, Netherlands
Stefano Fanti, Italy
Valérie Fonteyne, Belgium
Mark Rubin, Switzerland

LEARNING OBJECTIVES

- To learn about fundamentals of epidemiology, natural history and diagnosis as contributing factors to heterogeneity in prostate cancer
- To understand essentials in the assessment and multidisciplinary treatment of prostate cancer
- To learn about advances in treatment and novel targets in prostate cancer

ACCREDITATION

The programme of this event has been accredited with **9 ESMO-MORA category 1 points**.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



Thursday, 17 October 2019

09:00-09:15 15'	Opening and welcome	
15'	Welcome from ESMO - Objectives and scientific introduction	Karim Fizazi, FR
09:15-10:20 65'	SESSION 1 Screening, diagnosis and staging	Chairs: Valérie Fonteyne, BE Mark Rubin, CH
20'	PSA screening, diagnosis and staging classification	Theo M. de Reijke, NL
20'	Pathology and molecular classification for the clinician	Mark Rubin, CH
10'	Discussion	Faculty
15'	Participant clinical case discussion (1x15')	Faculty
10:20-10:50	Coffee break	
10:50-12:25 95'	SESSION 2 Localized prostate cancer	Chair: Elena Castro, ES
25'	Role of brachytherapy and radiotherapy and combination with ADT	Valérie Fonteyne, BE
20'	Role of surgery and other local treatments	Theo M. de Reijke, NL
20'	Active surveillance	Theo M. de Reijke, NL
30'	Participants clinical case discussion (2x15')	Faculty
12:25-13:30	Lunch	
13:30-15:00 90'	SESSION 3 Locally-advanced prostate cancer	Chairs: Silke Gillissen, CH Karim Fizazi, FR
5'	Case presentation with high-risk localized prostate cancer	Karim Fizazi, FR
	<u>Debate 1:</u> This house believes that high-risk localized prostate cancer should be treated with radiotherapy and Androgen Deprivation Therapy (ADT)	
10'	Arguments For	Valérie Fonteyne, BE
10'	Arguments Against and For surgery	Theo M. de Reijke, NL
5'	Case presentation of a patient with cN1	Karim Fizazi, FR
	<u>Debate 2:</u> This house believes that cN1 prostate cancer should be treated with surgery	
10'	Arguments For	Theo M. de Reijke, NL
10'	Arguments Against and For radiotherapy plus ADT	Valérie Fonteyne, BE
10'	Discussion	Faculty
30'	Participants clinical case discussion (2x15')	Faculty
15:00-15:30	Coffee break	

15:30-17:40 130'	SESSION 4 Systemic therapy	Chairs: Valérie Fonteyne, BE Karim Fizazi, FR
20'	ADT and other hormonal treatments, mechanisms of action, main efficacy results and toxicities	Silke Gillessen, CH
20'	Chemotherapy and Radium-223, mechanism of action, main efficacy results in Castration-Resistant Prostate Cancer (CRPC) and toxicities	Elena Castro, ES
20'	Bone health agents, mechanism of action, efficacy and toxicities	Karim Fizazi, FR
20'	Blood biomarkers (including PSA, CTC, cfDNA)	Elena Castro, ES
20'	Role of PET for staging, detecting relapses and assessing response to systemic treatment	Stefano Fanti, IT
30'	Participants clinical case discussion (2x15')	Faculty
19:00	Dinner	

Friday, 18 October 2019

09:00-10:30 90'	SESSION 5 Advanced prostate cancer	Chairs: Elena Castro, ES Theo M. de Reijke, NL
20'	Rising PSA after radical local treatment: Prognosis, indications for local and systemic treatments	Theo M. de Reijke, NL
20'	M0 CRPC: Prognosis and treatments	Karim Fizazi, FR
20'	Metastatic Castration-Sensitive Prostate Cancer (mCSPC)	Silke Gillessen, CH
30'	Participants clinical case discussion (2x15')	Faculty
10:30-11:00	Coffee break	
11:00-12:45 105'	SESSION 6 Metastatic disease	Chairs: Silke Gillessen, CH Elena Castro, ES
30'	Metastatic CRPC: Current treatment	Silke Gillessen, CH
30'	Immunotherapy and other new drug targets (including DNA repair, PSMA-therapy)	Karim Fizazi, FR
15'	Discussion: Sequencing of treatments	Faculty
30'	Participants clinical case discussion (2x15')	Faculty
12:45-13:00 15'	Conclusion and farewell	
13:00-14:00	Lunch	

Note: Each 15 minutes slot for clinical case discussion includes 7' case presentation and 8' Q&A / panel discussion